Business Context and Reporting Period
Company: Neurocrine Biosciences, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2007
Business Overview: Neurocrine discovers, develops, and intends to commercialize drugs for neurological and endocrine-related diseases. The company's lead clinical program is indiplon, a candidate for treating insomnia. Following the termination of a collaboration with Pfizer in late 2006, Neurocrine reacquired all worldwide rights to indiplon and is responsible for its development and commercialization.
Key Financial Metrics
| Metric (in thousands) | Six Months Ended June 30, 2007 | Six Months Ended June 30, 2006 |
|---|---|---|
| Total Revenues | $152 | $28,720 |
| Net Loss | $(52,084) | $(53,350) |
| Net Loss Per Share (Basic & Diluted) | $(1.37) | $(1.42) |
| Research & Development Expenses | $37,850 | $53,847 |
| Sales, General & Administrative Expenses | $17,124 | $31,731 |
| Cash and Cash Equivalents (End of Period) | $51,485 | $86,168 |
| Short-term Investments | $95,812 | $101,623 |
| Total Debt (Current + Long-term) | $51,204 | $53,641 |
| Net Cash Used in Operating Activities | $(33,607) | $(48,793) |
Material Changes vs. Prior Period
- Revenue Decline: Revenues dropped significantly from $28.7 million to $0.2 million for the six-month period. This is primarily due to the termination of the collaboration with Pfizer, which previously generated substantial revenue through sponsored development, license fees, and sales force allowances.
- Expense Reductions: Operating expenses decreased significantly. R&D expenses fell by $16.0 million and SG&A expenses fell by $14.6 million, driven by staff reductions and restructuring implemented in the third quarter of 2006.
- Net Loss Improvement: Despite the near-total loss of revenue, the net loss narrowed slightly from $53.4 million to $52.1 million due to the aforementioned cost-cutting measures.
- Liquidity: Cash and cash equivalents decreased by approximately $29.5 million, reflecting the net operating loss, partially offset by a reduction in accounts receivable.
Outlook, Risks, and Management Commentary
- Indiplon Regulatory Status: On June 12, 2007, the company resubmitted its New Drug Application (NDA) for indiplon 5 mg and 10 mg capsules. The FDA previously indicated these were "approvable" pending data reanalysis. The 15 mg tablet NDA remains "not approvable," requiring additional long-term safety and efficacy data. Management is formulating a strategy to pursue a sleep maintenance claim.
- Liquidity Outlook: Management believes existing capital resources ($147.3 million in cash and short-term investments) are sufficient to fund operations for at least the next 12 months. However, additional funding will be required for future development, and the company may seek strategic alliances or equity/debt financing.
- Legal Proceedings: Two class-action lawsuits and one shareholder derivative suit were filed in June 2007 alleging false statements regarding the progress of indiplon's FDA approval. The company intends to defend these actions, but the financial impact is currently not estimable.
- Asset Impairment Risk: The company holds a $94.0 million prepaid royalty asset related to indiplon. While no impairment was recognized as of June 30, 2007, management notes that further FDA delays or failure to commercialize could trigger a material impairment charge.
Investor Verification Checklist
- FDA Acceptance: Verify the FDA's formal response to the June 12, 2007 resubmission of the indiplon capsule NDA.
- Capital Runway: Monitor cash burn rates to confirm the 12-month liquidity projection remains valid given the lack of product revenue.
- Legal Exposure: Track the status of the securities class-action lawsuits filed in June 2007 regarding indiplon disclosures.
- Partnership Strategy: Assess progress in securing a new commercialization partner for indiplon, as the company must now fund development and marketing independently.
- Asset Valuation: Review future quarterly reports for any impairment charges related to the $94 million prepaid royalty asset.